Item request has been placed!
×
Item request cannot be made.
×
Processing Request
The Promise and Peril of Anti–Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibodies.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Additional Information
- Abstract:
The authors comment on a study published within the issue which examined the effectiveness of tixagevimab/cilgavimab for treatment of symptomatic COVID-19 or for post-exposure prophylaxis. Topics covered include the characteristics of study participants, the efficacy of monoclonal antibody across Omicron variants, and the strengths and limitations of the study.
No Comments.